Literature DB >> 2185154

A comparative study of cefamandole and ceftriaxone as prophylaxis in cardiac surgery.

P Neidhart1, V Velebit, K Gunning, P M Suter.   

Abstract

We compared the prophylactic use of cefamandole and ceftriaxone in 40 patients undergoing elective cardiac surgery. Postoperative wound infection occurred in one and two patients, respectively, in each group (n.s.), and bronchial superinfection in one patient in each group. In 12 additional patients drug concentrations in plasma and pericardial fluid were measured at different times following the administration of ceftriaxone. Plasma and pericardial fluid concentrations of ceftriaxone were above the minimal inhibitory concentration of susceptible microorganisms for up to 24 h after intravenous administration. We conclude, firstly, that the incidence of infection after cardiac surgery is low with both cefamandole and ceftriaxone prophylaxis. Secondly, efficient plasma and pericardial fluid levels of ceftriaxone last for up to 24 h after intravenous administration.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2185154     DOI: 10.1007/bf01641425

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  16 in total

1.  Comparative study between two prophylactic antibiotic regimens of cefamandole during coronary artery bypass surgery.

Authors:  P J van der Starre; P H Trienekens; J E Harinck-de Weerd; F T Willems; G J Kootstra; P J Huige; R F Quik
Journal:  Ann Thorac Surg       Date:  1988-01       Impact factor: 4.330

2.  A method for measurement of antibiotics in human interstitial fluid.

Authors:  J S Tan; A Trott; J P Phair; C Watanakunakorn
Journal:  J Infect Dis       Date:  1972-11       Impact factor: 5.226

3.  A scoring method (ASEPSIS) for postoperative wound infections for use in clinical trials of antibiotic prophylaxis.

Authors:  A P Wilson; T Treasure; M F Sturridge; R N Grüneberg
Journal:  Lancet       Date:  1986-02-08       Impact factor: 79.321

4.  Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults.

Authors:  A A Pollock; P E Tee; I H Patel; J Spicehandler; M S Simberkoff; J J Rahal
Journal:  Antimicrob Agents Chemother       Date:  1982-11       Impact factor: 5.191

Review 5.  The new beta-lactamase-stable cephalosporins.

Authors:  H C Neu
Journal:  Ann Intern Med       Date:  1982-09       Impact factor: 25.391

6.  Effective and creative surveillance and reporting of surgical wound infections.

Authors:  A B Kaiser
Journal:  Infect Control       Date:  1982 Jan-Feb

7.  Unreliability of fever and leukocytosis in the diagnosis of infection after cardiac valve surgery.

Authors:  D M Bell; D A Goldmann; C C Hopkins; A W Karchmer; R C Moellering
Journal:  J Thorac Cardiovasc Surg       Date:  1978-01       Impact factor: 5.209

8.  Prophylactic and preventive antibiotic therapy: timing, duration and economics.

Authors:  H H Stone; B B Haney; L D Kolb; C E Geheber; C A Hooper
Journal:  Ann Surg       Date:  1979-06       Impact factor: 12.969

9.  Penetration of ceforanide and cefamandole into the right atrial appendage, pericardial fluid, sternum, and intercostal muscle of patients undergoing open heart surgery.

Authors:  L D Mullany; M A French; C H Nightingale; H B Low; L H Ellison; R Quintiliani
Journal:  Antimicrob Agents Chemother       Date:  1982-03       Impact factor: 5.191

10.  Cefoxitin versus erythromycin, neomycin, and cefazolin in colorectal operations. Importance of the duration of the surgical procedure.

Authors:  A B Kaiser; J L Herrington; J K Jacobs; J L Mulherin; A C Roach; J L Sawyers
Journal:  Ann Surg       Date:  1983-10       Impact factor: 12.969

View more
  2 in total

Review 1.  Ceftriaxone: an update of its use in the management of community-acquired and nosocomial infections.

Authors:  Harriet M Lamb; Douglas Ormrod; Lesley J Scott; David P Figgitt
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  Ceftriaxone versus Other Antibiotics for Surgical Prophylaxis : A Meta-Analysis.

Authors:  Silvano Esposito; Silvana Noviello; Alessandro Vanasia; Paola Venturino
Journal:  Clin Drug Investig       Date:  2004       Impact factor: 2.859

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.